This study is in progress, not accepting new patients

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

a study on Cardiovascular Disease Heart Attack Stroke Coronary Revascularization

Eligibility: for people ages 18-99 (full criteria)
Location: at Los Angeles, California and other locations
Dates: study started October 2022
completion around May 2027
Principal Investigator: by Eric H. Yang, MD

Eric H. Yang

Description

Summary

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).

Official Title

EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction

Keywords

Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization, Acute Myocardial Infarction, Evolocumab, STEMI, NSTEMI, Heart Attack, Pragmatic, Cardiovascular Diseases, Infarction, Routine Lipid Management, Evolocumab + Routine Lipid Management

Eligibility

You can join if…

Open to people ages 18-99

Age greater than or equal to 18 years
Hospitalized for primary reason of NSTEMI or STEMI due to presumed atherosclerotic disease

You CAN'T join if...

Participants requiring invasive hemodynamic and/or vasopressor/inotropic support at the time of screening
Participants with elevated biomarkers of myocardial injury due to secondary/nonatherosclerotic etiology (eg, sepsis, atrial fibrillation, vasospasm, decompensated heart failure, uncontrolled hypertension, stress induced cardiomyopathy)

Locations

University of California Los Angeles
Los Angeles California 90095 United States
VA Greater Los Angeles Healthcare System
Los Angeles California 90073 United States

Lead Scientist at UCLA

Eric H. Yang, MD
Associate Professor of Clinical, Medicine. Authored (or co-authored) 168 research publications. Research interests: Cardio-Oncology · Medical Education · Valvular Disease · Interventional Echocardiography · Cardiac Computed Tomography

Details

Status: in progress, not accepting new patients
Start Date: October 2022
Completion Date: May 2027 (estimated)
Sponsor: Amgen
Links: AmgenTrials clinical trials website Sign up for this study
ID: NCT05284747
Phase: Phase 4 research study
Study Type: Interventional
Participants: About 6019 people participating
Last Updated: November 2024

I’m interested in this study!